Repurposing non-research facilities to house specialized life sciences and therapeutics labs is a growing trend sparked by real estate inventory and the fiscal practicality of renovation rather than new construction. The vacancy rate throughout the United States for lab space in the fourth quarter of 2022 was 6 percent versus 19.5 percent for office space, according to the Jones Lang LaSalle real estate transparency index. The vacancy rates for 2021 were less than 4 percent for labs and approximately 15 percent for offices.

Life science laboratories are increasingly embracing the idea of moving into high-rise settings in city centers, filling space in new construction, or renovating office space left vacant, in part, by the many companies opting to continue to work from home following the pandemic. High-rise laboratories in urban settings offer many advantages related to recruiting top talent, the ease of city amenities, and abundant transportation options, says Matthew Decker, AIA, architect for CRB in Plymouth Meeting, Penn. But they also pose challenges, including strict building codes for hazardous materials, and infrastructure concerns that can affect placement of lab equipment, HVAC systems, and utilities.

The Sixth Edition of the Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual emphasizes the importance of risk assessment and management, communication among all stakeholders, comprehensive procedures to report accidents and exposures, and a new focus on biocontainment of pathogens affecting agricultural animals. First published in 1984, the BMBL still serves as the cornerstone of biosafety practices for the safe conduct of research throughout the world.

The unprecedented health and economic impact of the COVID-19 pandemic is driving many institutions to increase investment in new biocontainment facilities or rapidly pivot to upgrade and repurpose existing containment spaces in an urgent attempt to respond to the crisis. Hundreds of organizations nationwide began applying for grants after the National Institutes for Health (NIH) received $3.6 billion in funding dedicated to COVID-19 research as part of an emergency stimulus bill passed earlier this year. The NIH now has until 2024 to release the funds. Additionally, private donors, non-governmental organizations, and other entities worldwide are providing billions in funding for development of testing and vaccine programs. This surge of financing is expected to fuel a growth in the creation of new biocontainment spaces in the near future and long term. Since designing, building, and commissioning new biocontainment labs is an expensive and time-consuming process, some institutions are electing to upgrade existing BSL-2 facilities to make them BSL-3, while others are choosing to move existing research programs to make room for new pandemic-related initiatives.